AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: Results of a phase II trial
Authors: Schmidinger, M Stager, G Wenzel, C Locker, GJ Budinsky, AC Brodowicz, T Kramer, G Marberger, M Zielinski, CC
Citation: M. Schmidinger et al., Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: Results of a phase II trial, J IMMUNOTH, 24(3), 2001, pp. 257-262
Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial
Authors: Hejna, M Kostler, WJ Raderer, M Steger, GG Brodowicz, T Scheithauer, W Wiltschke, C Zielinski, CC
Citation: M. Hejna et al., Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial, EUR J CANC, 37(16), 2001, pp. 1994-2002
Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancerpatients
Authors: Locker, GJ Wenzel, C Schmidinger, M Gnant, MFX Marosi, C Jakesz, R Zielinski, CC Steger, GG
Citation: Gj. Locker et al., Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancerpatients, ANTI-CANC D, 12(3), 2001, pp. 209-212
Difference in patient's acceptance of early versus late initiation of psychosocial support in breast cancer
Authors: Scholten, C Weinlander, G Krainer, M Frischenschlager, O Zielinski, CC
Citation: C. Scholten et al., Difference in patient's acceptance of early versus late initiation of psychosocial support in breast cancer, SUPP CARE C, 9(6), 2001, pp. 459-464
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial
Authors: Kostler, WJ Brodowicz, T Attems, Y Hejna, M Tomek, S Amann, G Fiebiger, WCC Wiltschke, C Krainer, M Zielinski, CC
Citation: Wj. Kostler et al., Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial, ANN ONCOL, 12(9), 2001, pp. 1281-1288
Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma
Authors: Reiter, WJ Brodowicz, T Alavi, S Zielinski, CC Kozak, W Maier, U Nost, G Lipsky, H Marberger, M Kratzik, C
Citation: Wj. Reiter et al., Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma, J CL ONCOL, 19(1), 2001, pp. 101-104
Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial
Authors: Schmidinger, M Budinsky, AC Wenzel, C Locker, GJ Pluschnig, U Brodowicz, T Kubista, E Maca, S Zabernigg, A Ilsinger, P Seewann, L Hojas, S Blach, M Zielinski, CC Steger, GG
Citation: M. Schmidinger et al., Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial, CANC CHEMOT, 47(1), 2001, pp. 57-62
Soluble ICAM-1 in breast cancer: clinical significance and biological implications
Authors: Kostler, WJ Tomek, S Brodowicz, T Budinsky, AC Flamm, M Hejna, M Krainer, M Wiltschke, C Zielinski, CC
Citation: Wj. Kostler et al., Soluble ICAM-1 in breast cancer: clinical significance and biological implications, CANCER IMMU, 50(9), 2001, pp. 483-490
Acceptance of medical information and contentment in cancer patients
Authors: Hejna, M Kostler, WJ Tomek, S Fiebiger, WCC Raderer, M Wiltschke, C Zielinski, CC
Citation: M. Hejna et al., Acceptance of medical information and contentment in cancer patients, WIEN KLIN W, 113(9), 2001, pp. 342-347
Oral mucositis complicating chemotherapy and/or radiotherapy: Options for prevention and treatment
Authors: Kostler, WJ Hejna, M Wenzel, C Zielinski, CC
Citation: Wj. Kostler et al., Oral mucositis complicating chemotherapy and/or radiotherapy: Options for prevention and treatment, CA-A CANC J, 51(5), 2001, pp. 290-315
Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2
Authors: Locker, GJ Kofler, J Stoiser, B Wilfing, A Wenzel, C Wogerbauer, M Steger, GC Zielinski, CC Mader, R Burgmann, H
Citation: Gj. Locker et al., Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2, EUR CYTOKIN, 11(3), 2000, pp. 391-396
Single-agent gemcitabine as second- and third-line treatment in metastaticbreast cancer
Authors: Brodowicz, T Kostler, WJ Moslinger, R Tomek, S Vaclavik, I Herscovici, V Wiltschke, C Steger, GG Wein, W Seifert, M Kubista, E Zielinski, CC
Citation: T. Brodowicz et al., Single-agent gemcitabine as second- and third-line treatment in metastaticbreast cancer, BREAST, 9(6), 2000, pp. 338-342
Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer
Authors: Brodowicz, T Wolfram, RM Kostler, WJ Tomek, S Vaclavik, I Steger, GG Teleky, B Fugger, R Jakesz, R Zielinski, CC
Citation: T. Brodowicz et al., Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer, ANTI-CANC D, 11(8), 2000, pp. 623-628
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer
Authors: Hejna, M Kostler, WJ Raderer, M Tomek, S Brodowicz, T Scheithauer, W Wiltschke, C Zielinski, CC
Citation: M. Hejna et al., Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer, ANTI-CANC D, 11(8), 2000, pp. 629-634
Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer
Authors: Brodowicz, T Koestler, WJ Tomek, S Vaclavik, I Herscovici, V Wiltschke, C Steger, GG Zielinski, CC
Citation: T. Brodowicz et al., Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer, ANTI-CANC D, 11(3), 2000, pp. 149-153
Vinorelbine and interferon-alpha 2c as second-line therapy in metastatic renal cell carcinoma
Authors: Schmidinger, M Steger, GG Budinsky, AC Wenzel, C Brodowicz, T Locker, GJ Kramer, G Marberger, M Zielinski, CC
Citation: M. Schmidinger et al., Vinorelbine and interferon-alpha 2c as second-line therapy in metastatic renal cell carcinoma, ANTI-CANC D, 11(3), 2000, pp. 175-179
Benefit of interferon-alpha(2b) in a patient with unresectable hepatoma and chronic infection with hepatitis C virus
Authors: Locker, GJ Mader, RM Steiner, B Wenzl, E Zielinski, CC Steger, GG
Citation: Gj. Locker et al., Benefit of interferon-alpha(2b) in a patient with unresectable hepatoma and chronic infection with hepatitis C virus, EUR J GASTR, 12(2), 2000, pp. 251-253
Detection of minimal residual disease in patients with cancer: A review oftechniques, clinical implications, and emerging therapeutic consequences
Authors: Kostler, WJ Brodowicz, T Hejna, M Wiltschke, C Zielinski, CC
Citation: Wj. Kostler et al., Detection of minimal residual disease in patients with cancer: A review oftechniques, clinical implications, and emerging therapeutic consequences, CANCER DET, 24(4), 2000, pp. 376-403
Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial
Authors: Schmidinger, M Steger, GG Wenzel, C Locker, GJ Brodowicz, T Budinsky, AC Wiltschke, C Kramer, G Marberger, M Zielinski, CC
Citation: M. Schmidinger et al., Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial, CANCER IMMU, 49(7), 2000, pp. 395-400
Transient increase in mitogen-induced lymphoproliferative responses in patients with testicular cancer after BEP chemotherapy
Authors: Krainer, M Wolf, HM Wiltschke, C Wilfing, B Kaider, A Kratzik, C Eibl, MM Zielinski, CC
Citation: M. Krainer et al., Transient increase in mitogen-induced lymphoproliferative responses in patients with testicular cancer after BEP chemotherapy, UROLOGY, 55(6), 2000, pp. 934-938
Glutathione in the prevention of cisplatin induced toxicities - A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer
Authors: Schmidinger, M Budinsky, AC Wenzel, C Piribauer, M Brix, R Kautzky, M Oder, W Locker, GJ Zielinski, CC Steger, GG
Citation: M. Schmidinger et al., Glutathione in the prevention of cisplatin induced toxicities - A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer, WIEN KLIN W, 112(14), 2000, pp. 617-623
Warfarin for cancer prevention
Authors: Zielinski, CC Hejna, M
Citation: Cc. Zielinski et M. Hejna, Warfarin for cancer prevention, N ENG J MED, 342(26), 2000, pp. 1991-1993
Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin
Authors: Leithner, A Schnack, B Katterschafka, T Wiltschke, C Amann, G Windhager, R Kotz, R Zielinski, CC
Citation: A. Leithner et al., Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin, J SURG ONC, 73(1), 2000, pp. 21-25
Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer
Authors: Wolfram, RM Budinsky, AC Brodowicz, T Kubista, M Kostler, WJ Kichler-Lakomy, C Hellan, M Kahlhammer, G Wiltschke, C Zielinski, CC
Citation: Rm. Wolfram et al., Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer, INT J CANC, 88(2), 2000, pp. 239-244
Inhibition of metastases by anticoagulants
Authors: Hejna, M Raderer, M Zielinski, CC
Citation: M. Hejna et al., Inhibition of metastases by anticoagulants, J NAT CANC, 91(1), 1999, pp. 22-36
Risultati: 1-25 | 26-33